Skip to main content

Advertisement

SpringerLink
Log in

Antifungal activity of nontraditional antifungal agents

  • Published:
Current Fungal Infection Reports Aims and scope Submit manuscript

Abstract

Invasive fungal infections are becoming increasingly important in the management of critically ill and immunocompromised patients. As organ and stem cell transplantation becomes more prominent and immune therapies are employed for diseases such as rheumatoid arthritis and plaque psoriasis, the population of patients at risk continues to grow. Many invasive fungal infections are associated with extremely high mortality rates. Antifungal options are limited and novel therapies are intriguing as we attempt to improve patient outcomes and preserve the antifungal armamentarium. Many other classes of pharmaceuticals typically seen as non-antifungal do in fact have significant antifungal activity. Prominent among these are calcineurin inhibitors, antiarrhythmics, antidepressants, antibacterials, and others. Some have activity alone and some augment the activity of conventional antifungals. Unfortunately, clinical data are lacking for most of these agents and their role in therapy remains undefined. This review focuses on several representative non-antifungal agents with antifungal activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Groll AH, McNeil Grist L: Current challenges in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki, Greece, 22–25 June 2008. Int J ntimicrob Agents 2009, 33:101–104.

    Article  CAS  Google Scholar 

  2. Cornely OA, Maertens J, Winston DJ, et al.: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356:348–359.

    Article  PubMed  CAS  Google Scholar 

  3. Ullmann A, Lipton J, Vesole D: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335–347.

    Article  PubMed  CAS  Google Scholar 

  4. Borisy AA, Elliott PJ, Hurst NW, et al.: Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003, 100:7977–7982.

    Article  PubMed  CAS  Google Scholar 

  5. Afeltra J, Meis JF, Vitale RG, et al.: In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species. Antimicrob Agents Chemother 2002, 46:2029–2031.

    Article  PubMed  CAS  Google Scholar 

  6. Yekutiel A, Shalit I, Shadkchan Y, Osherov N: In vitro activity of caspofungin combined with sulfamethoxazole against clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2004, 48:3279–3283.

    Article  PubMed  CAS  Google Scholar 

  7. Stergiopoulou T, Meletiadis J, Sein T, et al.: Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus. J Antimicrob Chemother 2009, 63:343–348.

    Article  PubMed  CAS  Google Scholar 

  8. Sasaki E, Maesaki S, Miyazaki Y, et al.: Synergistic effect of ofloxacin and fluconazole against azole-resistant Candida albicans. J Infect Chemother 2000, 6:151–154.

    Article  PubMed  CAS  Google Scholar 

  9. Nakajima R, Kitamura A, Someya K, et al.: In vitro and in vivo antifungal activities of DU-6859a, a fluoroquinolone, in combination with amphotericin B and fluconazole against pathogenic fungi. Antimicrob Agents Chemother 1995, 39:1517–1521.

    PubMed  CAS  Google Scholar 

  10. Nguyen MH, Clancy CJ, Yu YC, Lewin AS: Potentiation of antifungal activity of amphotericin B by azithromycin against Aspergillus species. Eur J Clin Microbiol Infect Dis 1997, 16:846–848.

    Article  PubMed  CAS  Google Scholar 

  11. Clancy CJ, Nguyen MH: The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998, 41:127–130.

    Article  PubMed  CAS  Google Scholar 

  12. Geraghty P, Kavanagh K: Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans. J Pharm Pharmacol 2003, 55:179–184.

    Article  PubMed  CAS  Google Scholar 

  13. Christenson JC, Shalit I, Welch DF, et al.: Synergistic action of amphotericin B and rifampin against Rhizopus species. Antimicrob Agents Chemother 1987, 31:1775–1778.

    PubMed  CAS  Google Scholar 

  14. Ben-Ami, R, Lewis R, Tarrand J, Kontoyiannis D: In vitro activity of colistin against Zygomycetes. Presented at the 2008 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; October 25–28, 2008.

  15. Watanabe T, Takano M, Ogasawara A, et al.: Anti-Candida activity of a new platinum derivative. Antimicrob Agents Chemother 2000, 44:2853–2854.

    Article  PubMed  CAS  Google Scholar 

  16. Cardenas ME, Cruz MC, Del Poeta M, et al.: antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev 1999, 12:583–611.

    PubMed  CAS  Google Scholar 

  17. Fekete-Forgacs K, Kis B, Nagy G, Lenkey B: Effect of fluconazole on the growth and adhesion of Candida albicans in the presence of antineoplastic agents. J Basic Microbiol 1999, 39:305–310.

    Article  PubMed  CAS  Google Scholar 

  18. Vitale RG, Afeltra J, Meis JF, Verweij PE: Activity and post antifungal effect of chlorpromazine and trifluopherazine against Aspergillus, Scedosporium, and Zygomycetes. Mycoses 2007, 50:270–276.

    Article  PubMed  CAS  Google Scholar 

  19. Wood NC, Nugent KM: Inhibitory effects of chlorpromazine on Candida species. Antimicrob Agents Chemother 1985, 27:692–694.

    PubMed  CAS  Google Scholar 

  20. Joseph JD, Means AR: Calcium binding is required for calmodulin function in Aspergillus nidulans. Eukaryot Cell 2002, 1:119–125.

    Article  PubMed  CAS  Google Scholar 

  21. Eilam Y, Polacheck I, Ben-Gigi G, Chernichovsky D: Activity of phenothiazines against medically important yeasts. Antimicrob Agents Chemother 1987, 31:834–836.

    PubMed  CAS  Google Scholar 

  22. Steinbach WJ, Reedy JL, Cramer RA, et al.: Harnessing calcineurin as a novel anti-infective agent against invasive fungal infections. Nat Rev Microbiol 2007, 5:418–430.

    Article  PubMed  CAS  Google Scholar 

  23. Sun S, Li Y, Guo Q, et al.: In vitro interactions between tacrolimus and azoles against Candida albicans determined by different methods. Antimicrob Agents Chemother 2008, 52:409–417.

    Article  PubMed  CAS  Google Scholar 

  24. Li Y, Sun S, Guo Q, et al.: In vitro interaction between azoles and cyclosporin A against clinical isolates of Candida albicans determined by the chequerboard method and time-kill curves. J Antimicrob Chemother 2008, 61:577–585.

    Article  PubMed  CAS  Google Scholar 

  25. Uppuluri P, Nett J, Heitman J, Andes D: Synergistic effect of calcineurin inhibitors and fluconazole against Candida albicans biofilms. Antimicrob Agents Chemother 2008, 52:1127–1132.

    Article  PubMed  CAS  Google Scholar 

  26. Kontoyiannis DP, Lewis RE, Osherov N, et al.: Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. J Antimicrob Chemother 2003, 51:313–316.

    Article  PubMed  CAS  Google Scholar 

  27. Singh N, Alexander BD, Lortholary O, et al.: Cryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortality. J Infect Dis 2007, 195:756–764.

    Article  PubMed  Google Scholar 

  28. Kontoyiannis DP, Lewis RE, Alexander BD, et al.: calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrob Agents Chemother 2008, 52:735–738.

    Article  PubMed  CAS  Google Scholar 

  29. Singh N, Gayowski T, Wagener M, et al.: Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. Transplantation 1996, 61:396–401.

    Article  PubMed  CAS  Google Scholar 

  30. Cruz MC, Del Poeta M, Wang P, et al.: Immunosuppressive and nonimmunosuppressive cyclosporine analogs are toxic to the opportunistic fungal pathogen Cryptococcus neoformans via cyclophilin-dependent inhibition of calcineurin. Antimicrob Agents Chemother 2000, 44:143–149.

    Article  PubMed  CAS  Google Scholar 

  31. Gupta SS, Ton VK, Beaudry V, et al.: Antifungal activity of amiodarone is mediated by disruption of calcium homeostasis. J Biol Chem 2003, 278:28831–28839.

    Article  PubMed  CAS  Google Scholar 

  32. Courchesne WE: Characterization of a novel, broad-based fungicidal activity for the antiarrhythmic drug amiodarone. J Pharmacol Exp Ther 2002, 300:195–199.

    Article  PubMed  CAS  Google Scholar 

  33. Afeltra J, Vitale RG, Mouton JW, Verweij PE: Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole. Antimicrob Agents Chemother 2004, 48:1335–1343.

    Article  PubMed  CAS  Google Scholar 

  34. Zhang YQ, Rao R: Global disruption of cell cycle progression and nutrient response by the antifungal agent amiodarone. J Biol Chem 2007, 282:37844–37853.

    Article  PubMed  CAS  Google Scholar 

  35. Baker CA, Desrosiers K, Dolan JW: Propranolol inhibits hyphal development in Candida albicans. Antimicrob Agents Chemother 2002, 46:3617–3620.

    Article  PubMed  CAS  Google Scholar 

  36. Song JL, Lyons CN, Holleman S, et al.: Antifungal activity of fluconazole in combination with lovastatin and their effects on gene expression in the ergosterol and prenylation pathways in Candida albicans. Med Mycol 2003, 41:417–425.

    Article  PubMed  CAS  Google Scholar 

  37. Chin NX, Weitzman I, Della-Latta P: In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 1997, 41:850–852.

    PubMed  CAS  Google Scholar 

  38. Natesan SK, Chandrasekar PH, Alangaden GJ, Manavathu EK: Fluvastatin potentiates the activity of caspofungin against Aspergillus fumigatus in vitro. Diagn Microbiol Infect Dis 2008, 60:369–373.

    Article  PubMed  CAS  Google Scholar 

  39. Rodrigues AA, Pina-Vaz C, Mårdh PA, et al.: Inhibition of germ tube formation by Candida albicans by local anesthetics: an effect related to ionic channel blockade. Curr Microbiol 2000, 40:145–148.

    Article  PubMed  CAS  Google Scholar 

  40. Pina-Vaz C, Rodrigues AG, Sansonetty F, et al.: Antifungal activity of local anesthetics against Candida Species. Infect Dis Obstet Gynecol 2000, 8:124–137.

    Article  PubMed  CAS  Google Scholar 

  41. Rodrigues AG, Araujo R, Pina-Vaz C: Interaction of local anaesthetics with other antifungal agents against pathogenic Aspergillus. Int J Antimicrob Agents 2006, 27:339–343.

    Article  PubMed  CAS  Google Scholar 

  42. Seto-Young D, Monk B, Mason AB, Perlin DS: Exploring an antifungal target in the plasma membrane H+-ATPase of fungi. Biochim Biophys Acta 1997, 1326:249–256.

    Article  PubMed  CAS  Google Scholar 

  43. Monk B, Mason AB, Abramochkin G, et al.: The yeast plasma membrane proton pumping ATPase is a viable antifungal target. I. Effects of the cysteine-modifying reagent omeprazole. Biochim Biophys Acta 1995, 1239:81–90.

    Article  PubMed  Google Scholar 

  44. Biswas S, Yokoyama K, Kamei K, et al.: Inhibition of hyphal growth of Candida albicans by activated lansoprazole, a novel benzimidazole proton pump inhibitor. Med Mycol 2001, 39:283–285.

    Article  PubMed  CAS  Google Scholar 

  45. Manavathu EK, Dimmock JR, Vashishtha SC, Chandrasekar PH: Inhibition of H+-ATPase-mediated proton pumping in Cryptococcus neoformans by a novel conjugated styryl ketone. J Antimicrob Chemother 2001, 47:491–494.

    Article  PubMed  CAS  Google Scholar 

  46. Manavathu EK, Dimmock JR, Vashishtha SC, et al.: In-vitro and in-vivo susceptibility of Aspergillus fumigatus to a novel conjugated styryl ketone. J Antimicrob Chemother 1998, 42:585–590.

    Article  PubMed  CAS  Google Scholar 

  47. Monk BC, Niimi K, Lin S, et al.: Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrob Agents Chemother 2005, 49:57–70.

    Article  PubMed  CAS  Google Scholar 

  48. Lass-Florl C, Dierich MP, Fuchs D, et al.: Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother 2001, 48:775–779.

    Article  PubMed  CAS  Google Scholar 

  49. Lass-Florl C, Dierich MP, Fuchs D, et al.: Antifungal Activity against Candida Species of the selective serotoninreuptake inhibitor, sertraline. Clin Infect Dis 2001, 33:e135–e136.

    Article  PubMed  CAS  Google Scholar 

  50. Young TJ, Oliver GP, Pryde D, et al.: Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity. J Antimicrob Chemother 2003, 51:1045–1047.

    Article  PubMed  CAS  Google Scholar 

  51. Cao YY, Dai B, Wang, Y, et al.: In vitro activity of baicalein against Candida albicans biofilms. Int J Antimicrob Agents 2008, 32:73–77.

    Article  PubMed  CAS  Google Scholar 

  52. Huang S, Cao YY, Dai BD, et al.: In vitro Synergism of fluconazole and baicalein against clinical isolates of Candida albicans resistant to fluconazole. Biol Pharm Bull 2008, 31:2234–2236.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. UK HealthCare Pharmacy Services, Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, 800 Rose Street, H110, Lexington, KY, 40536, USA

    Craig A. Martin

Authors
  1. William R. Judd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Craig A. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Craig A. Martin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Judd, W.R., Martin, C.A. Antifungal activity of nontraditional antifungal agents. Curr Fungal Infect Rep 3, 86–95 (2009). https://doi.org/10.1007/s12281-009-0012-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12281-009-0012-z

Keywords

Search

Navigation